高陽科技(00818.HK):Cloopen就存托股份擬於紐交所上市向美證券交易委員會提交註冊聲明
格隆匯 1 月 20日丨高陽科技(00818.HK)公吿,於2021年1月19日(紐約時間),Cloopen Group Holding Limited("Cloopen",一間公司於公佈日期實益擁有其約21.56%股權開曼羣島公司)根據1933年美國證券法(經修訂)就建議其美國存托股份於紐約證券交易所上市及發售("Cloopen交易")向美國證券交易委員會公開提交註冊聲明。
Cloopen交易並不構成公司根據上市規則第十四章進行交易,亦不構成上市規則第15項應用指引項下分拆。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.